Rapid Micro Biosystems, Inc. Stock Price, News & Analysis

Rapid Micro Biosystems (Nasdaq: RPID) will release third quarter 2025 financial results before market open on Friday, November 7, 2025.

The company's management will host a webcast conference call at 8:30 a.m. ET on November 7, 2025 to discuss results; the live audio webcast is accessible on the company website and will be archived for replay.

Trinity Capital (NASDAQ:TRIN) has committed $45 million in growth capital to Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for microbial quality control in healthcare product manufacturing. The funding will support Rapid Micro's global expansion of their Growth Direct® platform and investments in manufacturing efficiency improvements.

The Growth Direct® platform enhances microbial testing processes by providing faster results, improved accuracy, increased operational efficiency, and enhanced data integrity. The capital will be used to scale operations, support commercial expansion, and drive gross margin growth through cost reduction and improved manufacturing efficiency.

Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

The presentation is scheduled for Tuesday, September 9, 2025, at 11:00 a.m. ET in New York. Investors can access the live webcast through the company's investor relations website at investors.rapidmicrobio.com, with a replay available after the event.

Rapid Micro Biosystems (NASDAQ:RPID) reported Q2 2025 financial results, with total revenue reaching $7.3 million, up 10% year-over-year. The company demonstrated strong performance with recurring revenue growing 15% to $4.4 million and service revenue increasing 18% to $2.5 million.

The company secured a significant $45 million term loan facility with Trinity Capital, with $20 million funded at closing. Despite a net loss of $11.9 million, RPID showed improvement in gross margin, reaching positive 4% compared to negative 3% in Q2 2024. The company placed four new Growth Direct systems and completed two system validations during the quarter.

RPID reaffirmed its full-year 2025 revenue guidance of at least $32.0 million. The company ended Q2 with approximately $32 million in cash, cash equivalents, short-term investments, and restricted cash.

Rapid Micro Biosystems (NASDAQ:RPID) has secured a $45 million term loan facility with Trinity Capital Inc. The five-year facility includes an initial $20 million drawn at closing, with potential access to an additional $25 million in subsequent tranches.

The loan features an initial 11.5% annual floating interest rate with a 36-month interest-only period, extendable based on future tranche drawdowns. The funding will support the company's Growth Direct system commercial expansion, manufacturing efficiencies, and product cost reduction initiatives, aiming to strengthen its path toward positive cash flow.

Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has scheduled its Q2 2025 financial results announcement for August 12, 2025.

The company will release results before market open, followed by a management-hosted webcast conference call at 8:30 a.m. ET on the same day. The webcast will be available on the company's website and archived for future reference.

Rapid Micro Biosystems announced equity inducement grants to a new employee on June 2, 2025. The grants include 160,000 restricted stock units (RSUs) of Class A common stock and options to purchase 250,000 shares. The stock options have an exercise price of $3.45 per share, equal to the closing price on the grant date. The options will vest 25% after one year, followed by monthly vesting of 1/48th thereafter. RSUs will vest annually over three years, with one-third vesting each year. These grants were made under the Company's Inducement Plan and approved in accordance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new employee incentives.

Rapid Micro Biosystems (NASDAQ: RPID) has appointed Dr. Dafni Bika to its Board of Directors. Dr. Bika brings over 25 years of leadership experience in pharmaceutical development and manufacturing science. She currently serves as Senior Vice President and Global Head of Pharmaceutical Technology and Development at AstraZeneca plc, leading global teams in advancing synthetic molecules into approved medicines. Previously, she held senior executive roles at Bristol-Myers Squibb and served as Director of Global Pharmaceutical Commercialization at Merck. Dr. Bika holds a Ph.D. in Materials Science and Engineering from the University of Pennsylvania and will contribute to establishing the Growth Direct platform as the industry standard for automating pharmaceutical QC testing.

Rapid Micro Biosystems (NASDAQ: RPID) reported strong Q1 2025 financial results with total revenue of $7.2 million, representing a 28% growth year-over-year. The company achieved record quarterly service revenue of $3.1 million, up 64% from Q1 2024. Product revenue increased 10% to $4.1 million, while recurring revenue grew 6% to $4.0 million.

Notable achievements include placing three new Growth Direct® systems and completing nine customer system validations. Gross margin improved significantly to positive 6% from negative 27% in Q1 2024. Operating expenses decreased 5% to $12.1 million, and net loss improved to $11.3 million ($0.26 per share) from $13.3 million ($0.31 per share) year-over-year.

The company announced a global Distribution and Collaboration Agreement with MilliporeSigma and reaffirmed its 2025 revenue guidance of at least $32.0 million, targeting 21-25 system placements.